Gene Expression Study of Novel Chalcone in Breast Cancer Therapy

Abstract

The purpose of the current study was aimed to employ gene expression analysis to investigate the impact of chalcone derivatives on breast cancer cell lines. A series of synthesised chalcone derivatives were used for docking studies in order to identify the most effective chalones for cancer therapy. In accordance with the docking score data, the compound A7 ((2E)-3-(2-chloroquinolin-3-yl)-1-(5,6-dichloro-1H-benzimidazol-2-yl) prop-2-en-1-one) scored higher than other derivatives in EGFR target while the compound A32 ((2E)-3-(2-chloroquinolin-3-yl)-1-(5-fluoro-4-hydroxy-1H-1,3-benzimidazol-2-yl) prop-2-en-1-one) in aromatase target.

Epidermal growth factor receptor (EGFR) gene expression was studied using the compound A7 and aromatase gene expression were studied using the compound A32.  The A549 cell line was used in studies on the expression of the EGFR gene. In order to study the expression of the aromatase gene, MCF-7 cell line was used. A widely prevalent molecule in humans called glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is frequently employed as an endogenous reference gene in investigations of quantitative gene expression. The RTPCR data revealed that A32 did not produce a favourable response in aromatase gene study while A7 treatment with EGFR gene expression is effective against breast cancer.